ZyVersa Therapeutics, Inc. ZVSA
0.10
0.00
0.00%
as of 24 Sep
- Market cap
- $970.0K
- P/E
- 0.0×
Follow ZVSA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
0.03 | 0.15 | 0.33 | 0.78 | 0.06 | 0.04 | — |
Net Debt/EBITDA |
0.00 | 0.17 | 0.03 | 0.43 | 0.04 | (0.31) | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 556.77% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.45) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.21 | 0.80 | 0.08 | 0.20 | 0.63 | 0.41 | — |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| 1,289.40% | (96.10%) | (191.89%) | (55.60%) | 74.44% | 0.00% | — | |
| (238.24%) | (44.08%) | (151.11%) | (40.35%) | (892.39%) | (3,699.88%) | — | |
ROIC |
0.00% | (81.75%) | (848.52%) | (9.22%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
201.44% | 98.93% | 1,554.49% | 1,334.95% | 63.22% | 176.67% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.91 | 0.84 | 0.94 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.86) | (6.77) | (89.44) | (189.48) | (73.46) | (11.28) | — |
Cash per Share |
0.02 | 1.38 | 32.18 | 228.77 | 4.76 | 0.38 | — |
Shareholders Equity per Share |
(2.08) | 7.67 | 113.59 | 3,862.91 | (185.69) | (18.38) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(2.08) | 7.67 | 113.59 | 3,862.91 | (185.69) | (18.38) | — |
Free Cash Flow |
(5.11) | (7.52) | (8.72) | (4.89) | (5.08) | (5.25) | — |
Working Capital |
(12.39) | (9.52) | (6.84) | (1.83) | (12.81) | (7.22) | — |
Net Current Asset Value |
(12.39) | (10.37) | (7.69) | (12.48) | (13.15) | (8.90) | — |
| Other line items | |||||||
Quick Ratio |
0.01 | 0.14 | 0.31 | 0.72 | 0.02 | 0.02 | — |
Depreciation/Fixed assets |
— | 0.00 | 1,725.42 | 2.88 | 11.85 | 0.27 | — |
Cash ROIC |
41.63% | (74.84%) | (61.41%) | (4.65%) | 40.82% | 115.85% | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 81,142.31 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.86) | (6.77) | (89.44) | (189.48) | (73.46) | (11.28) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
9.73 | 8.88 | 7.23 | 4.01 | 2.16 | — | — |
Average Assets |
10.47 | 21.36 | 70.31 | 59.82 | 0.91 | 0.34 | — |
Average Common Equity |
(1.94) | 9.80 | 55.37 | 43.42 | (10.86) | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates